Temelimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
Temelimab (also known as GNbAC1[1]) is an experimental monoclonal antibody drug for immune system conditions that neutralizes the human endogenous retrovirus envelope protein HERV-W.[2][3] It has been studied for multiple sclerosis up to phase 2b, where it was found to be safe and to reduce brain lesions.[1] As of 2023, it is also being studied for cognitive impairment in long COVID.[4]
References
[edit]- 1 2 Irfan SA, Murtaza M, Ahmed A, Altaf H, Ali AA, Shabbir N, Baig MM (May 2022). "Promising role of temelimab in multiple sclerosis treatment". Multiple Sclerosis and Related Disorders. 61 103743. doi:10.1016/j.msard.2022.103743. PMID 35344907. S2CID 247489555.
- ↑ Mouliou DS, Dardiotis E (August 2022). "Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing?". Multiple Sclerosis and Related Disorders. 64 103938. doi:10.1016/j.msard.2022.103938. PMC 9169463. PMID 35717898.
- ↑ Kornmann G, Curtin F (December 2020). "Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review". Drug Safety. 43 (12): 1287–1296. doi:10.1007/s40264-020-00988-3. PMID 32794123. S2CID 221126453.
- ↑ Bonilla H, Peluso MJ, Rodgers K, Aberg JA, Patterson TF, Tamburro R, et al. (2023-03-09). "Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative". Frontiers in Immunology. 14 1129459. doi:10.3389/fimmu.2023.1129459. PMC 10034329. PMID 36969241.
 | This medical article is a stub. You can help Wikipedia by adding missing information. |